WFH: Closing the global gap - achieving optimal care

Haemophilia

Volumn 18, Issue SUPPL.4, 2012, Pages 1-12

  Skinner, Mark W ^a  

^a WORLD FEDERATION OF HEMOPHILIA   (Canada)

Author keywords

Global alliance for progress; Health outcomes analysis; Optimal care; WFH development model; WFH global survey; World federation of hemophilia

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ARTICLE; BLEEDING; BLEEDING DISORDER; COST OF ILLNESS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; EVIDENCE BASED MEDICINE; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEMOPHILIA; HUMAN; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MORBIDITY; MORTALITY; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; VON WILLEBRAND DISEASE;

DELIVERY OF HEALTH CARE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEMORRHAGIC DISORDERS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERNATIONAL AGENCIES; MALE; SOCIETIES, MEDICAL; WORLD HEALTH;

EID: 84862867193     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02822.x     Document Type: Article

References (54)

1. Schnabel F. Opening Address Delivered before the Delegates to the Copenhagen Conference to Form an International Haemophilia Organization. Copenhagen, Denmark, June 25, 1963.
2. World Federation of Hemophilia. Minutes for the First Meeting of the World Federation of Hemophilia. Copenhagen, Denmark, June 25-28, 1963.
3. World Federation of Hemophilia. Accredited National Member Organizations of the WFH. Montreal, QC, Canada: World Federation of Hemophilia, 2010.
4. National Hemophilia Foundation. Facts about Hemophilia. New York, USA: National Hemophilia Foundation, 1958.
5. National Hemophilia Foundation. For a Life Today and a Cure Tomorrow. New York, USA: National Hemophilia Foundation, 1958.
6. National Hemophilia Foundation. MASAC Medical Bulletin. New York, USA: National Hemophilia Foundation, 1965.
7. World Federation of Hemophilia. Report on the Annual Global Survey 2010. Montreal, QC, Canada: World Federation of Hemophilia, 2011.
8. Robert P. Projected trends in coagulation factors supply and demand. Presented at the WFH's 6th Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders, Montreal, Canada, September 24-25, 2009.
9. Michael Soucie J, Evatt Bruce, Jackson Debra, and the Hemophilia Surveillance System Project Investigators National Center for Infectious Diseases, Hematologic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia. Occurrence of Hemophilia in the United States. Am J Hematol 1998; 59: 288-94.
10. Kasper CK, Lin JC. How many carriers are there? Haemophilia 2010; 16: 842. doi:
11. Mauser Bunschoten EP, van Houwelingen JC, Sjamsoedin Visser EJ, van Dijken PJ, Kok AJ, Sixma JJ. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost 1988; 59: 349-52.
12. Plug I, Mauser-Bunschoten EP, Brocker-Vriends AHJT et al. Bleeding in carriers of hemophilia. Blood 2006; 108: 52-6.
13. Skinner MW. Building our global family - achieving treatment for all. Haemophilia 2010; 16: 1-10.
14. Lillicrap D. The Basic Science, Diagnosis, and Clinical Management of von Willebrand Disease, Treatment of Hemophilia Monograph 35. Second edition. Montreal, QC: World Federation of Hemophilia, 2008.
15. World Federation of Hemophilia. What Are Rare Clotting Factor Defi{ligature}ciencies? Montreal, QC: World Federation of Hemophilia, 2009.
16. U.S. Government, U.S. Census Bureau data. Accessed 1 December 2011.
17. Evatt B. Observations from Global Survey 2001: an emerging database for progress. Haemophilia 2002; 8: 153-6. doi: -2516.2002.00616.x.
18. European Directorate of the Quality of Medicines & HealthCare (EDQM). Proceedings of the International Symposium on the Optimal Clinical Use of Blood Components; April 24-25, 2009; p. 332. Available at Accessed April 17, 2012.
19. Skinner MW. WFH--the cornerstone of global development: 45years of progress. Haemophilia 2008; 14: 1-9.
20. World Federation of Hemophilia. Treatment for All: A Vision for Improvement. Montreal, Canada: World Federation of Hemophilia, 2006.
21. Evans di. Haemophilia Centers. BMJ 1982; 285: 1420.
22. World Health Organization. Delivery of Treatment for Haemophilia, Report of a Joint WHO/WFH/ISTH Meeting, London, UK, 11-13 February 2002. Geneva, Switzerland: World Health Organization, 2002.
23. World Federation of Hemophilia. Guidelines for the Management of Hemophilia. Montreal, QC: World Federation of Hemophilia, 2005.
24. Colvin BT, Astermark J, Fischer K et al., for The Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia 2008; 14: 361-74.
25. Evatt BL. The natural evolution of haemophilia care: developing and sustaining comprehensive care globally. Haemophilia 2006; 12: 13-21.
26. Soucie JM, Nuss R, Evatt B et al. Mortality among males with hemophilia: relations with source of medical care and the Hemophilia Surveillance System Project Investigators. Blood 2000; 96: 437-42.
27. World Health Organization (WHO). Constitution of the World Health Organization. Geneva: WHO, 1946.
28. Aledort L, Bullinger M, Von Mackensen S, Wasserman J, Young NL, Globe D on behalf of the Health Related Quality of Life Expert Working Group of the International Prophylaxis Study Group. Why should we care about quality of life in persons with haemophilia? Haemophilia 2012; 18: e154-e157. doi:
29. Evatt B. Guide to Developing a National Patient Registry. Montreal, QC, Canada: World Federation of Hemophilia, 2005.
30. Soucie, Michael J. Public health surveillance and data collection: general principles and impact on hemophilia care. Hematology 2012; 17: s144-s147. doi:10.1179/102453312X13336169156537.
31. Skinner MW. Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements. Br J Haematol 2011; 154: 704-714. doi:
32. O'Mahony B. Global haemophilia care challenge and opportunities. Presented at the XXV World Congress of the WFH, Seville, Spain, May 19-24, 2002.
33. World Federation of Hemophilia. Report on the Annual Global Survey 2003. Montreal, QC, Canada: World Federation of Hemophilia, 2004.
34. "What is GAP?". World Federation of Hemophilia. Available at Accessed April 20, 2012.
35. World Federation of Hemophilia. Treatment for All: Closing the gap in care for people with bleeding disorders 2012-2014. Montreal, Canada: World Federation of Hemophilia, 2012.
36. High KA, Skinner MW. Cell phones and landlines: the impact of gene therapy on the cost and availability of treatment for hemophilia. Mol Ther 2011; 19: 1749-50.
37. Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S; on Behalf of International Prophylaxis Study Group (IPSG) Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10. doi:
38. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Qrthop Scand Suppl 1965; 3-1: 32.
39. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
40. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
41. Fischer K. Optimizing efficacy of factor VIII prophylaxis for severe hemophilia A. Haemophilia 2011; 17: 1-24. doi:
42. Den Uijl IEM, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia 2011; 17: 41-4.doi:
43. Gringeri A, Lundin B, Mackensen SV, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thrombos Haemost 2011; 9: 700-10.
44. Stonebraker JS, Amand RE, Bauman MV, Nagle AJ, Larson PJ. Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand. Haemophilia 2004; 10: 18-26. doi:
45. SBU - Swedish Council on Health Technology Assessments. Treatment of hemophilia and von Willebrand Disease. 2011. Available at Accessed April 17, 2012.
46. Berntorp E, Astermark J, Baghaei F et al. Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment. Haemophilia 2012; 18: 158-65. doi:
47. Farrugia A, O'Mahony B, Cassar J. Health technology assessment and haemophilia. Haemophilia 2012; 18: 152-7. doi:
48. Farrugia A, Cassar J, Kimber MC, Balboni S. Treatment for life - Prophylaxis in Haemophilia A is more cost-effective than on-demand therapy in a cost-utility model. Late-Breaking Abstract of the XXXth International Congress of the World Federation of Hemophilia, Paris, France, July 8-12, 2012. Haemophilia 18: in press.
49. Stonebraker JS, Bolton-Maggs PHB, Michael Soucie J, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010; 16: 20-32.
50. Lillicrap D. The World Federation of Hemophilia and research. Haemophilia 2012; 18 (Suppl 4): 24-27.
51. EuroQuol Group. EQ-5D Questionnaire. Available at: Accessed May 17, 2012.
52. Noone D, O'Mahony B, Prihodova L. A survey of the outcome of prophylaxis, on-demand or combined treatment in 20-35year old men with severe haemophilia in four European countries. Haemophilia 2011; 17: e842-3. doi:
53. Khair K, Holland M, Vidler V, Loran C, Harrington C. Why don't haemophilia nurses do research? Haemophilia Article first published online 30 January 2012.
54. Skinner MW, Lillicrap DP, McMillan J, Castro Ozelo M, Pierce GF. What is a cure and how do we get there? Haemophilia 2004; 10: 115-8. doi: